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The Effect of Orally Administered Ranitidine and Once-Daily or Twice-Daily Orally 
Administered Omeprazole on Intragastric pH in Cats 
 
Zusammenfassung 
Einleitung: Magensäurehemmer wie Protonenpumpenhemmer und H2-Antihistaminika werden 
häufig bei Katzen mit Magenerkrankungen eingesetzt. Es ist unklar, inwieweit diese 
Medikamente den intragastrischen pH tatsächlich anheben. Die Ziele der Studie waren es, die 
säurehemmende Wirksamkeit von peroral verabreichtem Omeprazol (1 x tgl. versus 2 x tgl.) und 
Ranitidin auf den intragastrischen pH zu untersuchen.  
Material und Methode: In einer randomisierten Cross-Over-Studie wurde gesunden Katzen 
Omeprazol (1,1 bis 1,3 mg/kg q24h und q12h), Ranitidin (1,5 bis 2,3 mg/kg q12h) und Placebo 
verabreicht. Jeweils beginnend am Tag 4 der Behandlungen wurde der intragastrische pH-Wert 
kontinuierlich über 96 h mit dem Bravo™-System gemessen, gefolgt von einer medianen 
Auswaschphase von 12 Tagen. Der mittlere Prozentsatz der Zeit mit einem pH-Wert ≥3 und ≥4 
wurde innerhalb der Gruppen mittels Varianzanalyse für wiederholte Messungen verglichen.  
Resultate: Die Mittelwerte ± SD des Prozentsatzes der Zeit mit einem intragastrischem pH-Wert 
≥ 3 und ≥ 4 betrugen 67.0 ± 24.0 und 54.6 ± 26.4 für 2 x tgl. verabreichtes Omeprazol, 24.4 ± 
22.8 und 16.8 ± 19.3 für 1 x tgl. verabreichtes Omeprazol, 16.5 ± 9.0 und 9.6 ± 5.9 für Ranitidin 
und 9.4 ± 8.0 und 7.0 ± 6.6 für Placebo. 
Conclusio: Die Magensäuresekretion bei Katzen wird nur durch die 2 x tgl. perorale 
Verabreichung von Omeprazol signifikant gehemmt. Mit 1 x tgl. verabreichtem Omeprazol und 
Ranitidin kann keine effektive Säurehemmung erzielt werden.  
Stichwörter: Magensäurehemmer, Katzen, Omeprazol, Ranitidin. 
  
 
2 
 
 
Vetsuisse Faculty University of Zürich (2015) 
Sanja Šutalo 
Department for Small Animals, Clinic for Small Animal Internal Medicine  
msekey@vetclinics.uzh.ch 
 
The Effect of Orally Administered Ranitidine and Once-Daily or Twice-Daily Orally 
Administered Omeprazole on Intragastric pH in Cats 
 
Summary 
Introduction: Gastric acid suppressants, such as proton pump inhibitors and histamin receptor 
blockers, are frequently used in cats with acid-related gastric disorders, even though the efficacy 
of these drugs is largely unknown in this species. 
The goals of the present study were to investigate the effects of orally administered omeprazole 
and ranitidine on the intragastric pH in a placebo-controlled study and to compare once-daily and 
twice-daily dosage regimens for omeprazole in cats. 
Methods: In a randomized, 4-way crossover design, cats were given enteric coated omeprazole 
granules (1.1-1.3 mg/kg q24h and q12h), ranitidine (1.5-2.3 mg/kg q12h), and placebo. 
Intragastric pH was continuously monitored for 96 hours using the Bravo™ system, starting on 
day 4 of the treatment, and was followed by a median washout period of 12 days. Mean 
percentage of time pH was ≥3 and ≥4 was compared among groups using repeated measures 
ANOVA. 
Results: Mean ± SD percentage of time intragastric pH was ≥ 3 and ≥ 4 was 67.0 ± 24.0 and 54.6 
±26.4 for twice-daily omeprazole, 24.4 ± 22.8 and 16.8 ± 19.3 for once-daily omeprazole, 16.5 ± 
9.0 and 9.6 ± 5.9 for ranitidine, and 9.4 ± 8.0 and 7.0 ± 6.6 for placebo administration. 
Conclusion: Only the twice-daily oral omeprazole administration significantly suppressed gastric 
acid secretion in healthy cats, whereas once-daily omeprazole and standard doses of ranitidine 
cannot be considered effective acid suppressants in cats. 
Key words: Acid suppressant, Feline, Omeprazole, Ranitidine. 
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Introduction 
Acid-related gastric disorders result from an imbalance between gastric acid secretion and gastric acid 
mucosal defense mechanisms.
1 
In humans, gastric acidity plays an important role in gastric ulcer 
development, and numerous studies have been conducted on the efficacy of PO administration of acid-
suppressing drugs.
2 
In veterinary medicine, the role of gastric acidity in the pathogenesis of gastric erosive 
and ulcerative disease has received limited attention, and the most appropriate extent of gastric acid 
inhibition for acid-related diseases has yet to be determined in small animals.
3 
Although gastric erosive 
disease is commonly suspected in cats, especially in critically ill and stressed cats, it is difficult to confirm 
because of the inherent invasiveness of gastric mucosal visual inspection. Instead, gastric acid 
suppressants including histamine-2 receptor antagonists, such as ranitidine or famotidine, and proton 
pump inhibitors, such as omeprazole, are widely used empirically in this species.  
Although some information on the antisecretory effects of commonly used acid suppressants (e.g. 
omeprazole, famotidine, ranitidine) is available for dogs,
4–6 
the clinical efficacy of antisecretory drugs in 
cats is largely unknown. The Existing data on feline gastric pH, derived from studies that used the cat as a 
model for humans, are difficult to interpret because gastric acid secretion was pharmacologically modified 
or experiments were carried out in anesthetised cats that had been vagotomized, and pH measurements 
were determined for only a few hours.
7–10 
Despite the relative paucity of studies in cats, acid suppressant 
medications are commonly used in clinical practice, using dosages extrapolated from studies performed in 
dogs.
4,5 
 
The recent introduction of pH monitoring devices such as the Bravo
TM 
system
a 
has allowed noninvasive, 
continuous assessment of intragastric pH over prolonged periods. This technique has been evaluated for 
extended recordings of intragastric pH in dogs.
4,11 
The effects of twice-daily omeprazole versus standard 
dosages of famotidine on intragastric pH in cats recently have been reported using this new technique. The 
Results of this study indicated that omeprazole administration provided superior acid suppression 
compared with famotidine.
12 
 
The goals of the present study were to determine normal gastric acid profiles in healthy cats, to investigate 
the effect of omeprazole and ranitidine on intragastric pH in a placebo-controlled study and to compare 
once-daily and twice-daily dosage regimens for omeprazole.  
We hypothesized that omeprazole would be superior to ranitidine for achieving a sustained increase in 
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gastric pH and that omeprazole administered twice daily would provide superior gastric acid control 
compared with a once-daily dosage regimen.  
Materials and Methods  
Cats  
Eight healthy European shorthair cats (2 intact females, 3 spayed females, 3 intact males), aged 5–6 years 
(median, 5.7 years) and weighing 4.3–6.8 kg (median, 5.3 kg) with median body condition score of 5/9, 
were used. All cats were research colony cats from the Institute of Animal Nutrition of our institution. The 
cats had no clinical signs of gastrointestinal disease for the past 6 months and were deemed healthy based 
on physical examination findings as well as the results of CBC, serum biochemistry profile and urinalysis. 
The study was approved by the Cantonal Veterinary Office of Zürich and conducted in accordance with 
the guidelines established by the Animal Welfare Act of Switzerland (permission no. 527/2013). 
Permission for the use of animals in our study specified that cats with anorexia, vomiting persisting >24 
hours, weight loss exceeding 10% of body weight, or some combination of those would be excluded. 
During intragastric pH recording periods, pairs of cats were housed in 140 x 105 x 100 cm cages and had 
daily physical exercise.  
Study Design  
Using a randomized cross-over design, cats received 1 of the following treatments PO for 7 consecutive 
days: placebo (empty gelatin capsule)
b 
q12h, ranitidine
c 
(1.5–2.3 mg/kg; median, 1.9 mg/kg) q12 h, 
omeprazole
d 
(1.1–1.3 mg/kg; median, 1.2 mg/ kg) q24h, or omeprazole
d 
(1.1–1.3 mg/kg; median, 1.2 
mg/kg) q12 h. The goal of treatment was to achieve a dosage of approximately 1 mg/kg for omeprazole, 
thus, 1 enteric-coated granule containing 1.1 mg omeprazole was given per kg body weight (e.g. a 10 mg 
omeprazole capsule
d 
contained 9 enteric-coated granules each consisting of 1.1-mg omeprazole).
e 
The 
dosage of each drug was consistent among treatments for each cat. All drugs were administered in hard 
gelatin capsules.
b 
To facilitate swallowing, approximately 1 teaspoon of a highly palatable feline food
f 
was fed immediately after administration of the capsule. Cats were medicated daily at 6:30 am and 6:30 
pm, 30 minutes before a standardized morning and evening meal.
g 
The once-daily omeprazole treatment 
was given in the morning. One of the authors (SŠ) stayed with the cats for a minimum of 45 minutes after 
treatment to ensure that medication was not regurgitated or vomited. Each treatment period was followed 
by a median washout period of 12 days (range, 7–24 days). Attitude, appetite, body weight, number of 
defecations, and fecal consistency were recorded daily. Feces were graded from 1 to 7 (1, very hard; 7, 
watery) according to a standardized fecal scoring system.
h 
 
5 
 
On day 4 of each treatment period, cats were anesthetized after a 12-hour fast for endoscopy-assisted 
placement of a pH capsule.
a 
Cats were premedicated with butorphanol
i 
(0.2 mg/kg IM) and medetomidine
j 
(5 lg/kg IM), an IV catheter was placed, and general anesthesia was induced with propofol and maintained 
with isoflurane. Before the first pH capsule placement, routine gastric and duodenal endoscopic biopsy 
was performed. The biopsy samples were fixed in 10% buffered formalin, embedded in paraffin, cut into 
2-µm sections and stained using a routine protocol with hematoxylin and eosin. Gastrointestinal biopsy 
specimens were assessed by a board-certified pathologist (MR) according to World Small Animal 
Veterinary Association guidelines.
13 
All pH capsules were placed under direct endoscopic guidance by the 
same investigator (PHK). Immediately before placement, the capsules were calibrated with commercial 
buffer solutions (pH 1.07 and 7.01) according to the manufacturer’s instructions.
a 
A drift of 0.1 pH units 
was tolerated. All pH capsules were anchored in the fundic area using the supplied delivery system that 
combined suction and a lock-and-pin mechanism.  
The approach for gastric capsule placement was similar to what has been described recently in dogs,
4,11 
with the exception that the external vacuum suction (510 mm Hg) applied to the capsule delivery system 
was decreased from approximately 30 seconds to a median of 20 seconds during the study.
k 
After capsule 
placement, gastric pH recordings were obtained telemetrically at 6-second sampling intervals for 4 days 
(96 hours). The receiver was kept in close proximity outside of the feline’s cage. After acquisition, pH 
data were uploaded from the receiver to the computer using the manufacturer software.
l 
Percentage of time 
intragastric pH was ≥3 and ≥4 and in 1 of each of 8 categories (pH 0–1, pH 1–2, up to pH 7–8) was 
calculated by the computer software. Throughout the study, all cats were subjected to visual inspection 4 
times daily and were allowed to play in a separate enclosure twice daily. A chaperone (SŠ) was present 
during these times to entertain the cats and to ensure that the distance to the receiver was adequate.  
Investigation of Capsule Dissolution  
Because all medications were administered in hard gelatin capsules
b
, an experiment was conducted to 
examine the drug release time at different pH levels. Dissolution of gelatin capsules containing enteric-
coated omeprazole granules
d 
and ranitidine
c 
was examined visually in transparent cups containing 35 ml 
of phosphate-buffered saline (PBS) buffer solution that was warmed to body temperature (37.5 °C) and 
had a pH of 1, 2, 3, 4, 5, 6, or 7.  
Statistical Analyses  
Commercially available software
m 
was used for analysis. Repeated measures ANOVA was used to 
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analyze differences among the 4 treatment arms regarding (1) percentage of time intragastric pH was ≥3 
and ≥4 during the 96-hour period after pH capsule placement (days 4–7 of treatment), (2) percentage of 
time intragastric pH was in 1 of 8 pH categories (0–1, 1–2, 2–3, 3–4, 4– 5, 5–6, 6–7, 7–8) for days 4–7 of 
treatment; and (3) adverse effects of treatments by comparing the 7-day mean number of defecations with 
fecal scores ≥3 and ≥4.  
In a second analysis, the different treatment arms were assessed separately and the effect of day was 
evaluated with repeated measures ANOVA. Assumption of sphericity was examined by Mauchly’s test of 
sphericity and a Bonferroni correction was applied to multiple comparisons. Differences were considered 
significant at P < 0.05.  
Results  
Cats  
All cats were alert and active and had a normal appetite throughout the study. A single episode of 
vomiting occurred 2 days after Bravo
TM 
capsule placement in 1 of the cats in the twice-daily omeprazole 
treatment arm.  
Assessment of Fecal Scores  
The occurrence of fecal scores >3 and >4 did not differ among treatment arms. The median fecal score 
was 3 for the placebo, 4 for ranitidine, 4 for once-daily treatment with omeprazole, and 4 for twice-daily 
administration of omeprazole.  
Experience with the Bravo
TM 
System
a 
in Cats  
Overall, 32 Bravo
TM 
capsules were successfully attached to the fundic mucosa. Total procedure times for 
endoscopy-assisted capsule placement ranged from 5 to 8 minutes, with most procedures taking <5 
minutes. In 1 cat, the stomach still contained food, and mucosal capsule attachment was unsuccessful 
because food remnants obstructed the suction hole. Capsule placement and pH measurement were 
repeated at a later time point. In 4 cases, the previously attached capsule was still in place at the time of 
the subsequent pH measurement (Fig. 1). Because endoscopic removal of the capsule with the help of 
endoscopic foreign body retrieval devices and polypectomy forceps was unsuccessful in the first case, a 
new capsule was attached next to the other 1 in these 4 cats. No problems were encountered with this 
approach. Passing of pH capsules through the digestive tract was verified by daily fecal examination in all 
cats. A total of 2,909 hours and 20 minutes of intragastric pH recording time (equivalent to 1,745,580 pH 
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readings) was obtained. The maximum possible data acquisition was 3,072 hours (96 hours per cat per 
treatment). Therefore, the overall missing data rate was 5.3%. Missing data were caused by signal 
interference in the radiotelemetric system, which occurred intermittently in all treatment groups.  
Endoscopic and Histologic Assessment of Gastrointestinal Biopsy Samples  
Gastroduodenoscopic evaluation was normal in all cats. Histologic examination of endoscopic gastric 
biopsy samples showed severe colonization of the mucosal surface with spiral-shaped organisms 
interpreted as gastric Helicobacter spp. in all of the cats. There were no concurrent lesions in the mucosa 
or lamina propria. The villi of the intestine were slender and had normal architecture with a crypt-to-villi 
ratio of 1:4. The epithelium was normal but in the lamina propria, small clusters of 9–12 neutrophils per 
high power field (hpf) were observed in 5 cats. The remaining 3 cats had smaller clusters of 4–5 
neutrophils per hpf scattered in the lamina propria. The final histologic diagnosis was gastric colonization 
by Helicobacter spp. Duodenal tissue was deemed normal.  
Assessment of Capsule Dissolution  
The capsules started to swell within 2 minutes of being placed in the PBS buffer solution. Complete 
disintegration of the capsules and release of the contents occurred within 5 minutes at all pH levels.  
Intragastric pH Recordings  
With respect to percentage of time intragastric pH was ≥3 and ≥4, twice-daily omeprazole had a 
significantly greater effect than once-daily omeprazole, ranitidine, and placebo administration. There were 
no significant differences among the latter 3 treatment arms.  
Mean ± SD percentage of time intragastric pH was ≥3 and ≥4 was 67.0 ± 24.0% and 54.6 ± 26.4% for 
twice-daily omeprazole administration, 24.4 ± 22.8% and 16.8 ± 19.3% for once-daily omeprazole 
administration, 16.5 ± 9.0% and 9.6 ± 5.9% for ranitidine administration, and 9.4 ± 8.0 and 7.0 ± 6.6% for 
placebo administration (Fig. 2).  
The treatment arms differed with respect to the distribution of intragastric pH over pH categories 1–8 (Fig. 
3). For pH category 1–2, twice-daily omeprazole administration differed significantly from the other 
treatment arms (placebo, P = 0.02; once-daily omeprazole, P = 0.024; ranitidine, P = 0.040). For 
categories 3–4, 4–5, 5–6, and 6–7, twice-daily omeprazole differed significantly from placebo, and for pH 
categories 4–5, 5–6, and 6–7, ranitidine differed significantly from placebo. To summarize, intragastric 
pH ranged widely across all pH categories with all treatments; but twice-daily omeprazole resulted in the 
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largest amount of time intragastric pH was in categories 3–4 to 6–7.  
Comparison of treatment days within a given treatment identified a significant increase in intragastric pH 
between days 4 and 7 only for twice-daily omeprazole (P = 0.011 for pH ≥3; P = 0.044 for pH ≥4).  
Discussion  
Although more commonly encountered in dogs, gastric erosive and ulcerative disease can exacerbate a 
range of gastrointestinal, metabolic, or neoplastic conditions
14 
or be a complication of nonsteroidal 
antiinflammatory drug administration in cats.
15 
Gastric acid suppressants currently are the treatment of 
choice for these conditions. Because information on the efficacy of antisecretory drugs is scarce in cats,
9,b 
the goal of the present study was to compare the effects of PO administered gastric acid suppressants 
commonly used in cats. Our study clearly demonstrated that twice-daily omeprazole administration 
provided superior gastric acid suppression compared with a once-daily dosage regimen and with standard 
dosages of ranitidine and placebo based on percentage of time intragastric pH was ≥3 and ≥4. The 
conceptual basis for these cut-offs has been explored by meta-analysis of many trials in human medicine, 
and these cut-offs are now considered ideal for promoting optimal gastrointestinal ulcer healing.
16,17 
Comparison of once-daily and twice-daily omeprazole administration was chosen because additional drug 
administration could pose a substantial problem for sick cats and would likely result in poor owner 
compliance. A twice-daily dosage regimen used in small animals has been largely extrapolated from 
studies of humans.
18 
A simplified omeprazole suspension (enteric-coated granules suspended in 8.4% 
sodium bicarbonate) administered to dogs as a bolus through a stomach tube resulted in superior gastric 
acid suppression over 24 hours compared with once-daily omeprazole.
5 
Another study in dogs found that 
the effect of once-daily administration of reformulated omeprazole paste used in horses for gastric acid 
secretion waned substantially during 24 hours after administration.
4 
It therefore was postulated that a 
twice-daily dosage regimen was more beneficial. It was surprising that the once-daily dosage of 
omeprazole in the present study had poor results in cats because comparable omeprazole dosages in dogs 
yielded a mean percentage of time with intragastric pH ≥3 of 70.2% and ≥4 of 52.3%.
5 
Species-specific 
differences such as increased de novo biosynthesis of proton pumps may account for this difference 
because restoration of acid secretion is dependent on pump biosynthesis.
18 
Delayed gastric release of 
omeprazole from the gelatin capsule with inadequate intestinal absorption caused by variability in the 
hardness of the capsule wall
n 
was ruled out as a cause of the unexpected low intragastric pH because the 
capsules were shown to dissolve quickly at all pH levels.  
The effects of ranitidine and placebo on intragastric pH did not differ in the present study, which is in 
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contrast to a recent report that PO administered famotidine in cats had better antisecretory efficacy than 
placebo.
b 
Ranitidine and famotidine were shown to have poor antisecretory properties in dogs.
4,5 
We 
anticipated similar results, based on observations that plasma gastrin concentrations did not increase in 
cats undergoing long-term ranitidine treatment.
9 
This indicates that ranitidine has weak antisecretory 
properties because gastrin release is inhibited by the presence of acid in the stomach by a negative 
feedback mechanism. Nevertheless, we felt it was important to provide substantial evidence that ranitidine 
also is a weak acid suppressant in cats and therefore should not be used for treatment of acid-related 
gastric disorders in cats.  
We used enteric-coated omeprazole granules rather than splitting tablets because a dosage of 1 mg/kg can 
be more easily approximated by administering 1 granule per kg body weight (1 granule contains 1.1 mg 
omeprazole),
d 
which is convenient in small patients. Omeprazole granules are also used in human 
pediatric patients and when medication must be given through a feeding tube.
19–21 
Moreover, it was felt 
that splitting enteric-coated omeprazole tablets may adversely affect drug efficacy. However, results 
published during the course of the present investigation showed that fractionated enteric-coated 
omeprazole tablets remained effective acid suppressants in cats despite disruption of the enteric coating.
12 
 
To facilitate swallowing of the capsule, a teaspoon of highly palatable canned feline food
f 
was fed 
immediately after pill administration. Administration of water by syringe usually is recommended after 
oral drug administration in cats.
22 
However, the cats in our study did not tolerate syringe feeding of water, 
but readily ate the small amount of food.
f
 This procedure is likely more practical for owners who 
administer drugs to their cats at home, and we do not believe that the small amount of food compromised 
the efficacy of the medication. The administration of omeprazole granules to children in an acidic or 
alkaline solution or mixed with apple sauce resulted in acid suppression comparable with that of intact 
capsules in humans.
19,23 
Similarly, a study of omeprazole absorption in humans indicated that the area 
under the curve of omeprazole was similar, and that the total amount of drug absorbed was not affected 
when the granules were given immediately before or after breakfast.
24 
 
We chose the Bravo
TM 
pH monitoring system
a 
because we found it reliable and minimally invasive for 
extended continuous gastric pH monitoring in dogs.
11 
This system allows longer measurement periods 
than catheter-based pH probes.
5 
Compared with dogs, a shorter vacuum application time (approximately 
20 seconds) worked better for pH capsule placement in cats. In the 4 cats with pH capsules still in place at 
the time of second capsule application, the vacuum was applied for ≥25 seconds, and we believe a larger 
part of the gastric mucosa became lodged in the suction well of the capsule (Fig. 1) compared with what 
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we observed in dogs.
11 
Inclusion of the lamina muscularis may have added to the rigidity of the 
attachment. Attempts to remove the first capsule failed, and we left them in place. We were aware of a 
case of gastric perforation related to endoscopic removal of a Bravo
TM 
capsule,
25,a 
and it is possible that 
our attempts at removal were too conservative.  
Soft feces has been associated with PO administered omeprazole treatment in humans and dogs,
4,5,26 
but 
how suppression of gastric acid secretion predisposes patients to this adverse effect is not well understood. 
We used fecal score cut-offs of 3 and 4 and found that the treatments did not differ with respect to feces 
consistency.  
Histologic examination of gastric and duodenal biopsy samples was done to rule out occult 
gastrointestinal disease that could have interfered with parietal cell function or duodenal drug absorption. 
In all cats, the gastric mucosa was heavily colonized with Helicobacter spp., but no evidence of gastritis 
was observed. In humans, the relationship between gastritis caused by H. pylori and gastric acid secretion 
is controversial, and normal acid secretion as well as hyper- and hypo-chlorhydria have been reported.
1 
Although the severity of gastritis did not seem to be correlated with gastric acid secretion, omeprazole 
treatment resulted in higher gastric pH in human patients infected with H. pylori than in patients free of H. 
pylori.
27 
This effect of omeprazole is believed to be present because of the neutralization of substances 
produced by H. pylori.
27 
We believe this scenario to be unlikely in the cats of our study because H. pylori 
infection is extremely rare in cats
28 
and evidence of gastritis was not detected in the present study. Given 
the overall high prevalence of gastric mucosal colonization with Helicobacter spp. without concurrent 
gastritis in cats,
28 
we concluded that gastric histology results were typical of what is seen in cats. The 
principal goal of histologic examination was to rule out occult gastric disease, which could have affected 
gastric acid secretion, and small bowel disease,
29 
which could have affected drug absorption. The 
relationship between gastric acid secretion and Helicobacter spp. colonization in cats requires further 
study.  
A significant increase in intragastric pH between days 4 and 7 was only recorded after twice-daily 
omeprazole administration, which was similar to reports in humans in which multiple omeprazole doses 
were needed for optimal effect.
23,30 
True drug efficacy might be greater after multiple doses than what we 
were able to document during the 96-hour study period. Considering the strong and long-lasting 
attachment of the capsule to the gastric mucosa in cats when using a vacuum time >25 seconds, it should 
be possible to study the efficacy of gastric acid suppressants for longer than 4 days.  
We saw considerable individual variation in response to treatment with omeprazole and much less so with 
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ranitidine. For example, 1 cat consistently had close to 100% acid suppression (e.g. percentage of time pH 
was ≥4 was 95% when treated with twice-daily omeprazole), whereas another had extremely poor acid 
suppression (percentage of time pH was ≥4 was 3% when treated with twice-daily omeprazole). These 
findings are similar to those observed in humans
23,31 
and may be a consequence of genetic polymorphism 
in the hepatic cytochrome P-450 system involved in the metabolism of omeprazole, which is a well-
established explanation for people who do not respond to gastric acid suppressants.
32 
In fact, recent 
studies on the acid suppressant effects of proton pump inhibitors in humans include analysis of 
cytochrome 450 genes and report pH measurements based on results of genotyping (i.e. extensive, 
intermediate, and poor metabolizers).
33  
The washout periods used in the present study varied slightly among treatments subject to staff 
availability. However, we feel that the protocols used in our experiments precluded drug carryover effects. 
The minimum washout period of 7 days (n = 5) pertained to 3 examinations preceded by placebo and 2 
preceded by ranitidine. The next shortest washout period was 9 days (n = 2), pertaining to 2 examinations 
preceded by once-daily omeprazole. A minimum of 1 week washout period was chosen because full 
restoration of gastric acid secretion was shown 7 days after long-term administration of ranitidine in cats
9 
and 5 days after long-term administration of omeprazole in people.
34 
 
In conclusion, twice-daily administration of omeprazole granules appears to be the treatment of choice for 
cats with acid-related gastrointestinal disease. Ranitidine and once-daily omeprazole cannot be 
recommended as acid suppressants in cats.  
Footnotes  
a 
Bravo
TM
 pH monitoring system, Given Imaging, Yoqneam, Israel.  
b 
Gelatin capsules size 5, Interdelta SA, 1762 Givisiez, Switzerland.  
c 
Ranitidin 20 mg, Christoffel-Apotheke, Christoffelgasse 3, 3001 Bern, Switzerland.  
d 
Omezol-Mepha MT 10, Mepha Pharma AG, 4010 Basel, Switzerland.  
e 
email communication with Ms. Linda Kötter-Spirgi (07.24.2014), Mepha Pharma AG, 4010 Basel, 
Switzerland.  
f 
Hill’s Prescription Diet Canine/Feline a/d.  
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g 
Hill’s Science Diet Optimal Care Original Adult Cat Food.  
h 
Faecal Scoring System, Nestle Purina PetCare Company, St Louis, MO, USA.  
i 
Morphasol, Graeub AG, Rehhagstrasse 83, 3018 Bern, Switzerland. 
j 
Dorbene, Graeub AG, Rehhagstrasse 83, 3018 Bern, Switzerland.  
k 
email communication with Dr. Katie Tolbert (21.10.2013) 
l 
Polygram Net Software, Given Imaging, Yoqneam, Israel. 
m 
SPSS, version 11, SPSS Inc, Chicago, IL, USA. 
n 
https://www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html  
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Fig. 1 View of the Bravo
TM 
capsule attached to the feline gastric mucosa. Compared to dogs,
11 
comparatively large parts of the gastric mucosa became lodged in the suction well of the capsule.  
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Fig. 2 Comparison of efficacy of various treatments on intragastric pH. Box plots show variation in 
percentage of time intragastric pH was ≥3 (blue) and ≥4 (green) for 8 cats given placebo, ranitidine, once-
daily omeprazole and twice-daily omeprazole. *Results were significantly increased compared with 
placebo, ranitidine, and once-daily omeprazole (P = 0.011 for pH ≥3; P = 0.044 for pH ≥4).  
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Fig. 3 Box plots representing the intragastric pH distribution for 8 cats receiving placebo, ranitidine, once-
daily omeprazole, and twice-daily omeprazole. Circles represent outliers.  
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